About Promopharm
Promopharm is a publicly listed company based in Casablanca (Morocco) founded in 1985, and was acquired by Hikma in October 2011. Pharmaceutical, dermo-pharmaceutical, and cosmetology products are manufactured and distributed. Its chief executive, as recorded, is Brahim Oulammou. Promopharm offers products and services including Medicines and Contract Manufacturing Services. Its focus areas include Diversified Pharmaceuticals. Its legal entity is Promopharm S.A.
Company details
Promopharm SA was established in 1985 in Casablanca, Morocco, as an industrial pharmaceutical company. Medicinal products, dermo-pharmaceuticals, and cosmetology items are produced, marketed, represented, imported, and exported. Partnerships with international pharmaceutical firms are utilized for manufacturing and distributing licensed products, alongside research and development activities. High-end products are manufactured and distributed, and subcontracting services are provided for drugs on behalf of national and international laboratories.
- Headquarters Casablanca, Morocco
- Stage Acquired
- SectorsHealthcare
- Website promopharm.co.ma
- Social LinkedIn YouTube
- Acquired by Hikma (Oct 2011)
- Legal Name Promopharm Sa
Products & Services of Promopharm
Promopharm offers a comprehensive portfolio of products and services, including Medicines and Contract Manufacturing Services.
High-quality generic medicines for various health treatments and accessibility.
Production of injectables and generics for pharmaceutical partners.
Apps and channels of Promopharm
its YouTube channel Hikma Pharmaceuticals has 12.8K subscribers and 30 videos.
Videos from Promopharm
The most watched videos on Promopharm's YouTube channel, Hikma Pharmaceuticals (12.8K subscribers). Click a video to play it here.
More on Hikma Pharmaceuticals.
Investors in Promopharm
Promopharm has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Hikma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Generics and pharmaceutical products are manufactured by Hikma. | 1978 | hikma.com | Amman, Jordan |
Investor details for Promopharm
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Promopharm
1 people are tracked at Promopharm (1 in leadership).
| Name | Role | Group |
|---|---|---|
Brahim Oulammou | CEO | Leadership |
Complete people profiles for Promopharm
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Promopharm
Promopharm is a publicly listed company on the CSEMA with ticker symbol PRO in Morocco, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jun 2007
- Listed onCSEMA: PRO
- Listed entityPromopharm SA
- Exchange sectorHealth technology
- ISINMA0000011660
- Share price1,300.00 MAD (-1.29% on the day) · 2026-05-11
- Market capitalisation1,300,000,000.00 MAD
- Price to earnings21.7
- EPS (diluted, trailing year)59.91 MAD
- Volume (last session)134
- Analyst consensusNo rating
Financials of Promopharm
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 979.7M MAD | 59.9M MAD | 159.8M MAD |
| 2024 | 898.7M MAD | 55.2M MAD | 158.1M MAD |
| 2023 | 805.5M MAD | 56.9M MAD | 142.2M MAD |
| 2022 | 704.6M MAD | 75.3M MAD | 164.9M MAD |
| 2021 | 630.5M MAD | 69.0M MAD | 133.8M MAD |
Detailed financial statements for Promopharm
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Promopharm
3 dated milestones of Promopharm across 26 years, from founding to its latest funding, stage changes and deals.
- Founded Promopharm is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Hikma.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Promopharm
Promopharm was founded in 1985.
Promopharm is headquartered in Casablanca, Morocco.
Brahim Oulammou is the CEO of Promopharm, as recorded in our data.
Promopharm SA was established in 1985 in Casablanca, Morocco, as an industrial pharmaceutical company. Medicinal products, dermo-pharmaceuticals, and cosmetology items are produced, marketed, represented, imported, and exported. Partnerships with international pharmaceutical firms are utilized for manufacturing and distributing licensed products, alongside research and development activities. High-end products are manufactured and distributed, and subcontracting services are provided for drugs on behalf of national and international laboratories.
Promopharm offers Medicines and Contract Manufacturing Services.
Yes, Promopharm is publicly traded on CSEMA under the ticker symbol PRO.
Promopharm has 1 investor. Key investors include Hikma.
Promopharm operates through Promopharm S.A..
Yes. Promopharm was acquired by Hikma in October 2011.